Search
21/03/2024
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Rueda, AG, Taus, A, Alvarez, RA, Bernabé-Caro, R, Chara, L, López-Brea, M, Vilà, L, González, MAS, Aldagalán, ADD, Herrera, BE, Castro, RL, Cabellos, RA, Doménech, M, Falagan, S, Vega, AM, Aguado, C, Barba, A, Ureña, MTD, Isla, D, Hernández, LB, Pérez, JLF, Juan-Vidal, O, Massuti, B, Mielgo-Rubio, X, Ortega, AL, Catot, S, Dómine, M, Escoín-Pérez, C, Navalón, FG, Gil-Bazo, I, Muñoz, S, Rodríguez-Abreu, D, Roldán, RMV, Curbera, GA, León-Mateos, L, Padilla, A, Lario, AP, Sánchez-Torres, JM, Garrido, P. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9)DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2.500(Q3/6D).
21/03/2024
Cost-effectiveness of active tuberculosis screening among high-risk populations in low tuberculosis incidence countries: a systematic review, 2008 to 2023
Gogichadze, N, Sagrera, A, Vicente, JA, Millet, JP, López-Segui, F, Vilaplana, C. Cost-effectiveness of active tuberculosis screening among high-risk populations in low tuberculosis incidence countries: a systematic review, 2008 to 2023. Eurosurveillance. 2024; 29(12)DOI:10.2807/1560-7917.ES.2024.29.12.2300614. PMID:38516785. IF:7.800(Q1/1D).
20/03/2024
Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium
Larsen, FK, Baksh, RA, Mcglinchey, E, Langballe, EM, Benejam, B, Beresford-Webb, J, Mccarron, M, Coppus, A, Falquero, S, Fortea, J, Levin, J, Loosli, SV, Mark, R, Rebillat, AS, Zaman, S, Strydom, A. Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium. ALZHEIMERS & DEMENTIA. 2024; 20(5)DOI:10.1002/alz.13779. PMID:38506627. IF:11.100(Q1/1D).
19/03/2024
Prognostic Utility of Society for Cardiovascular Angiography and Interventions Shock Stage Approach for Classifying Cardiogenic Shock Severity in Takotsubo Syndrome
Camblor-Blasco, A, Nuñez-Gil, IJ, Cambra, AD, Almendro-Delia, M, Ródenas-Alesina, E, Feráandez-Cordon, C, Vedia, O, Corbí-Pascual, M, Blanco-Ponce, E, Raposeiras-Roubin, S, Marzo, MG, Flecha, ASG, Acuña, JMG, Salamanca, J, Escudier-Villa, JM, Martin-Garcia, AC, Tomasino, M, Vazirani, R, Perez-Castellanos, A, Uribarri, A. Prognostic Utility of Society for Cardiovascular Angiography and Interventions Shock Stage Approach for Classifying Cardiogenic Shock Severity in Takotsubo Syndrome. Journal of the American Heart Association. 2024; 13(6)DOI:10.1161/JAHA.123.032951. PMID:38471832. IF:5.300(Q1/2D).
19/03/2024
Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids
Sánchez, JM, López-Laguna, H, Parladé, E, Somma, AD, Livieri, AL, Alamo, P, Mangues, R, Unzueta, U, Villaverde, A, Vázquez, E. Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids. Advanced Science. 2024; 11(21)DOI:10.1002/advs.202309427. PMID:38501900. IF:14.100(Q1/1D).
18/03/2024
European expert consensus recommendations on the primary care use of direct oral anticoagulants in patients with venous thromboembolism
Carter, P, Fuat, A, Haas, S, Smyth, Elizabeth, Brotons, C, Cools, F, Bauersachs, R, Hobbs, R. European expert consensus recommendations on the primary care use of direct oral anticoagulants in patients with venous thromboembolism. Bmc Primary Care. 2024; 25(1)DOI:10.1186/s12875-024-02314-7. PMID:38500048. IF:2.600(Q1/1D).